Table 1.

Effects of Nilotinib and Everolimus on Orthotopic TMK-1 Tumors per Treatment Group.

Group	Body Weight (g)	Tumor Incidence	Tumor Weight (g)	Lymph Node Metastasis
Control	21.8 (17.8–24.6)	5/5	0.33 (0.07–0.72)	3/5
Nilotinib (100 mg/kg)	20.6 (18.5–23.5)	5/5	0.35 (0.10–0.45)	4/5
Everolimus (2 mg/kg)	22.0 (20.4–23.9)	4/6	0.08 (0.00–0.15)*	3/6
Nilotinib (100 mg/kg) + everolimus (2 mg/kg)	21.3 (16.3–22.1)	1/6	0.006 (0.00–0.04)†	0/6

Control group (n = 5), nilotinib group (n = 5), everolimus group (n = 6), and nilotinib plus everlimus group (n = 6).

Ranges are shown in parentheses.

^*P < .05 versus control group values.

^†P < .01 versus control group values.